ADMA Biologics Inc (NASDAQ:ADMA) Receives $18.67 Consensus PT from Brokerages

ADMA Biologics Inc (NASDAQ:ADMA) has been given an average recommendation of “Moderate Buy” by the six analysts that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $18.6667.

A number of equities analysts recently issued reports on the stock. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Zacks Research raised shares of ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Raymond James Financial began coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price objective for the company. Finally, Mizuho reduced their price objective on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th.

Trending Headlines about ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: No company-specific positive catalyst was reported in the latest news batch; the main focus remains on litigation risk.
• Neutral Sentiment: ADMA short-interest data was reported as unchanged/limited, offering little clear trading signal on its own.
• Negative Sentiment: Several law firms announced or reiterated securities-fraud class actions against ADMA Biologics, adding legal uncertainty and potential financial risk. Article Title
• Negative Sentiment: Reports alleging channel stuffing and misrepresentations about growth expectations may further damage investor confidence in ADMA Biologics. Article Title

ADMA Biologics Price Performance

ADMA stock opened at $8.27 on Wednesday. The company has a market cap of $1.92 billion, a price-to-earnings ratio of 12.16 and a beta of 0.73. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95. The business’s 50-day moving average is $8.48 and its two-hundred day moving average is $11.89. ADMA Biologics has a fifty-two week low of $7.21 and a fifty-two week high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.19. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The business had revenue of $114.49 million during the quarter, compared to the consensus estimate of $139.98 million. During the same period in the previous year, the company posted $0.11 EPS. The business’s quarterly revenue was down .3% compared to the same quarter last year. As a group, analysts forecast that ADMA Biologics will post 0.8 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Jerrold B. Grossman purchased 12,500 shares of the business’s stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $8.01 per share, with a total value of $100,125.00. Following the completion of the acquisition, the director owned 513,884 shares of the company’s stock, valued at approximately $4,116,210.84. This trade represents a 2.49% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 3.90% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Summit Securities Group LLC purchased a new stake in ADMA Biologics in the 4th quarter worth approximately $29,000. Optima Capital LLC bought a new stake in shares of ADMA Biologics during the 4th quarter valued at $36,000. iSAM Funds UK Ltd bought a new position in ADMA Biologics in the 3rd quarter worth $34,000. Morse Asset Management Inc bought a new position in ADMA Biologics in the 4th quarter worth $44,000. Finally, Nkcfo LLC bought a new position in ADMA Biologics in the 4th quarter worth $47,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.